Global Prostate Cancer Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Prostate Cancer Diagnostics Market is presumed to reach the market size of nearly USD 16.55 Billion by 2032 from USD 9.13 Billion in 2023 with a CAGR of 6.83% under the study period 2024-2032.

Prostate cancer is among the most frequent cancer type in the male. This cancer appears in the prostate in a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. Health practitioners do tests to analyze and comprehend the seriousness and learn if malignant growth has spread to other body locations from where it started. Doctors may also do tests to know which treatments could work best. Most prostate cancers are first found due to screening with PSA tests, CTC tests, immunohistochemistry, digital rectal exam, imaging test, and PCA3 test.

MARKET DYNAMICS

The rising prevalence of prostate cancer worldwide is driving the global prostate cancer diagnostics market. Prostate cancer is the fifth dominating cause of death worldwide and the second most frequent cancer diagnosis made in men. According to GLOBOCAN estimates, in 2018, 1,276,106 new prostate cancer cases were reported globally, with a higher burden in the developed countries. Differences in the prevalence rates worldwide reflect differences in the use of diagnostic testing. However, lack of awareness, high cost of diagnosis, and inadequate healthcare facilities in rural areas hinder the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Prostate Cancer Diagnostics. The growth and trends of Prostate Cancer Diagnostics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Prostate Cancer Diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Test Type

Preliminary Tests (PSA Tests, Free PSA Test, Total PSA Test, Other Preliminary Tests)
Confirmatory Tests (Pca3 Test, Trans-Rectal Ultrasound, Biopsy Test)

By Type Outlook

Adenocarcinoma
Interstitial Cell Carcinoma
Other

By End Use

Hospitals
Outpatient Facilities
Home Care
Research & Manufacturing

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Prostate Cancer Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prostate Cancer Diagnostics market include MDx Health, Myriad Genetics Inc., Abbott Laboratories, F. Hoffman-La Roche AG, Bayer AG, Siemens Healthcare GmbH, OPKO Health Inc., Genomic Health., Pfizer Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11213873

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PROSTATE CANCER DIAGNOSTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Test Type
- 3.7.2 Market Attractiveness Analysis By Type Outlook
- 3.7.3 Market Attractiveness Analysis By End Use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET ANALYSIS BY TEST TYPE

5.1. Overview By Test Type
5.2. Historical and Forecast Data
5.3. Analysis By Test Type
5.4. Preliminary Tests (PSA Tests, Free PSA Test, Total PSA Test, Other Preliminary Tests) Historic and Forecast Sales By Regions
5.5. Confirmatory Tests (Pca3 Test, Trans-Rectal Ultrasound, Biopsy Test) Historic and Forecast Sales By Regions

6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET ANALYSIS BY TYPE OUTLOOK

6.1. Overview By Type Outlook
6.2. Historical and Forecast Data
6.3. Analysis By Type Outlook
6.4. Adenocarcinoma Historic and Forecast Sales By Regions
6.5. Interstitial Cell Carcinoma Historic and Forecast Sales By Regions
6.6. Other Historic and Forecast Sales By Regions

7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET ANALYSIS BY END USE

7.1. Overview By End Use
7.2. Historical and Forecast Data
7.3. Analysis By End Use
7.4. Hospitals Historic and Forecast Sales By Regions
7.5. Outpatient Facilities Historic and Forecast Sales By Regions
7.6. Home Care Historic and Forecast Sales By Regions
7.7. Research & Manufacturing Historic and Forecast Sales By Regions

8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PROSTATE CANCER DIAGNOSTICS COMPANIES

9.1. Prostate Cancer Diagnostics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PROSTATE CANCER DIAGNOSTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. MDx Health
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Myriad Genetics Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Abbott Laboratories
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. F. Hoffman-La Roche AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Bayer AG
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Siemens Healthcare GmbH
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. OPKO Health Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Genomic Health.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Pfizer Inc
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies